Natural Health Trends Corp. — Q3 2012 Form 10-Q
Reporting period: Three and nine months ended September 30, 2012; balance-sheet figures are as of September 30, 2012, compared with December 31, 2011. Amounts below are U.S. dollars, rounded to millions unless stated otherwise.
Business context
The company sells NHT Global personal care, wellness and lifestyle products through e-commerce and an independent distributor network. It reported approximately 21,000 active distributors. About 95% of net sales came from outside North America; Hong Kong accounted for 72% of Q3 sales. Management identified Greater China and Russia/Kazakhstan as priority markets.
Financial performance
| Metric | Q3 2012 | Q3 2011 | Nine months 2012 | Nine months 2011 |
|---|---|---|---|---|
| Net sales | $9.33m | $10.56m | $29.40m | $22.95m |
| Gross profit | $6.95m | $8.03m | $21.74m | $16.90m |
| Gross margin | 74.5% | 76.0% | 73.9% | 73.7% |
| Operating income | $0.79m | $1.22m | $2.23m | $1.50m |
| Net income | $0.75m | $1.63m | $2.10m | $1.82m |
| EPS, basic and diluted | $0.07 | $0.15 | $0.19 | $0.17 |
Q3 distributor commissions were $3.90m, or 41.7% of sales, versus 39.4% a year earlier. For the nine-month period, commissions were $12.47m, or 42.4% of sales, versus 37.7%. SG&A was $2.26m in Q3 and $7.01m year to date. The filing reports no debt balance; current liabilities totaled $6.51m.
Cash flow and liquidity
- Nine-month operating cash flow was $1.60m, compared with $1.44m in 2011. Investing activities provided $0.41m, mainly from the release of restricted cash; financing activities were nil.
- Cash and cash equivalents were $3.65m, up from $1.62m at year-end 2011. Current assets were $5.52m; working capital remained in deficit by $0.99m, with a current ratio of 0.85. Excluding deferred revenue, the ratio was 0.96.
- Stockholders’ equity improved from a deficit of $0.81m at year-end to positive equity of $1.39m. Management believed available liquidity and operating cash flows would fund normal operations and commitments for at least 12 months, assuming no significant unforeseen expense or revenue decline.
Changes, outlook and risks
- Q3 sales fell 12% year over year, primarily as Hong Kong sales declined 20%; the company attributed part of the comparison to prior-year 10th-anniversary promotions and events. Nine-month sales rose 28%, including 35% growth in Hong Kong and 24% growth in Russia.
- Q3 gross margin declined 1.5 percentage points. Management cited prior-year event ticket sales and, excluding that effect, higher importation and logistics costs associated with a greater Russian sales mix. Year-to-date gross margin edged up 0.2 percentage points.
- Management attributed higher commission rates to Hong Kong payout increases and recognition-program promotions, as well as higher payouts in Russia. Q3 other income shifted from a $0.43m gain in 2011 to a $0.03m expense in 2012, largely reflecting foreign-exchange effects.
- No formal financial guidance was provided. The company had no direct-selling license in China; its applications had not materially progressed, and the company could not predict whether or when a license would be granted. It warned that regulatory interpretations or enforcement could restrict China-related e-commerce or member activity. Hong Kong sales are heavily connected to buyers in China.
- Other stated exposures include foreign-currency movements, distributor retention and compensation, product and direct-selling regulation, third-party manufacturing and supply, and potential cash-flow pressure or need for external financing. Management reported effective disclosure controls and no material internal-control changes; no legal proceedings were reported.
Unusual items and potential dilution
- Vendor settlements and other adjustments generated SG&A credits of $0.14m in Q3 and $0.21m for the first nine months of 2012.
- The company was considering royalty and license terms with Broady Health Sciences, an entity connected to director George Broady, for the Restor product. A proposed 2.5% royalty would imply approximately $31,000 for 2011 and the first nine months of 2012; no definitive agreement was disclosed.
- At September 30, 3.70m warrants remained outstanding. The filing describes different warrant terms and expirations; potential exercise could dilute shareholders. A distributor stock-purchase plan bought 34,770 shares in September at an average $1.35, with $13,142 remaining under that plan; a separate employee plan contemplated purchases of 100,000 shares.
Important facts for investors to verify
- Whether Hong Kong and China-related demand can be sustained, given the concentration of sales and the unresolved Chinese direct-selling license and regulatory risks.
- Whether higher distributor commission rates, foreign-exchange effects and Russian logistics costs will continue to pressure margins.
- How the working-capital deficit, operating cash generation and management’s 12-month liquidity assumption develop.
- The final terms and related-party approval process, if any, for the proposed Restor royalty arrangement, and the potential dilution from outstanding warrants and stock plans.